At this point, only mAbs for CD20-positive B cell (Blontress®) or CD52 positive T cell lymphoma (Tactress®) are approved by the US Department of Agriculture and commercially available in the USA and Canada (12). Here, CD52 is linked to T-cell non-Hodgkin lymphoma.